文献速递关节外科

美国髋膝关节置换临床试验主要研究者中女性代表性不足

Women Are Underrepresented Among Principal Investigators of Hip and Knee Arthroplasty Clinical Trials in the United States.
PubMed 文献 · J Bone Joint Surg Am · 2023-06-14

该研究查询了2015年至2021年ClinicalTrials.gov上的髋膝关节置换临床试验,纳入由美国骨科医生担任主要研究者(PI)的157项试验、192名PI。结果显示仅2名(1.0%)PI为女性,女性PI的参与-患病比(PPR)为0.16,提示代表性不足,而男性PPR为1.06。作者结论认为女性在髋膝关节置换临床试验PI中代表性不足,可能影响学术晋升,需更多研究了解女性领导临床试验的潜在障碍。

要点

  • 192名髋膝关节置换临床试验PI中仅2名(1.0%)为女性。
  • 符合条件的男性骨科教员中78.2%(190/243)担任PI,女性仅11.8%(2/17),差异有统计学意义(p < 0.001)。
  • 女性PI在助理教授(PPR=0.0)、副教授(PPR=0.52)和正教授(PPR=0.58)各层级均代表性不足。

核心结论

  • 女性在髋膝关节置换临床试验主要研究者中代表性不足,可能导致学术晋升与发展的差异。
  • 需要更多研究来理解女性领导临床试验的潜在障碍。
  • 需要提高认识和参与度,以在髋膝关节置换研究的临床试验领导中实现性别公平。

研究设计与样本

  • 对2015年至2021年ClinicalTrials.gov上的髋膝关节置换临床试验进行查询。
  • 纳入标准为涉及美国骨科医生主要研究者的临床试验。
  • 共纳入157项临床试验,涉及192名关节置换主要研究者。
  • 分析初级(助理教授)和高级(副教授或正教授)教员的性别代表性,并计算参与-患病比(PPR),PPR <0.8表示代表性不足,PPR >1.2表示代表性过度。

主要发现

  • 192名主要研究者中仅2名(1.0%)为女性。
  • 主要研究者经费来源多为学术机构(66%)和产业(33%),美国联邦来源资助少数(1%)主要研究者。
  • 符合条件的243名男性关节置换教员中190名(78.2%)担任主要研究者;符合条件的17名女性关节置换教员中仅2名(11.8%)担任主要研究者(p < 0.001)。
  • 整个关节置换主要研究者队列中,女性代表性不足(PPR = 0.16),男性代表性公平(PPR = 1.06)。
  • 女性在助理教授(PPR = 0.0)、副教授(PPR = 0.52)和正教授(PPR = 0.58)层级均代表性不足。

关键数值与推荐

  • PPR <0.8表示代表性不足,PPR >1.2表示代表性过度。
  • 女性主要研究者PPR = 0.16,男性主要研究者PPR = 1.06。
  • 女性在助理教授层级PPR = 0.0,副教授层级PPR = 0.52,正教授层级PPR = 0.58。

临床怎么用

  • 女性在关节置换主要研究者中代表性不足可能导致患者外科医生选择减少,并可能限制某些患者人群获得肌肉骨骼诊疗。
  • 多元化的关节置换队伍可促进对历史上代表性不足和脆弱患者人群不成比例影响的问题的关注。

局限性

  • 需要更多研究来理解女性领导临床试验的潜在障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Leadership of clinical trials confers national recognition and promotes academic advancement. We hypothesized that women would be underrepresented among principal investigators (PIs) of hip and knee arthroplasty clinical trials in the United States. METHODS: A query of hip and knee arthroplasty clinical trials from 2015 to 2021 was performed on ClinicalTrials.gov. Clinical trials were included if they involved a U.S.-based orthopaedic-surgeon PI. We analyzed the sex representation of arthroplasty PIs among junior-level (assistant professor) and senior-level (associate or full professor) faculty. Participation-to-prevalence ratios (PPRs) were calculated by comparing the sex representation among arthroplasty PIs with that among academic arthroplasty faculty at institutions conducting hip and knee arthroplasty clinical trials. A PPR of <0.8 indicated underrepresentation and a PPR of >1.2 indicated overrepresentation. RESULTS: A total of 157 clinical trials involving 192 arthroplasty PIs were included. Of these PIs, only 2 (1.0%) were women. PIs were mostly funded by academic institutions (66%) and industry (33%). U.S. federal sources funded a minority (1%) of PIs. Of the 243 male arthroplasty faculty who were eligible, 190 men (78.2%) served as PIs. In contrast, of the 17 female arthroplasty faculty who were eligible, only 2 women (11.8%) served as PIs (p < 0.001). Across the entire cohort of arthroplasty PIs, women were underrepresented (PPR = 0.16), whereas men were equitably represented (PPR = 1.06). Women were underrepresented at the assistant professor (PPR = 0.0), associate professor (PPR = 0.52), and full professor (PPR = 0.58) levels. CONCLUSIONS: Women were underrepresented among PIs of hip and knee arthroplasty clinical trials, which may lead to disparities in academic promotion and advancement. More research is needed to understand the potential barriers to female leadership of clinical trials. Greater awareness and engagement are needed to create sex equity in clinical trial leadership for hip and knee arthroplasty research. CLINICAL RELEVANCE: The underrepresentation of women among arthroplasty PIs may lead to fewer options in surgical providers for patients and may limit access to musculoskeletal care for certain patient populations. A diverse arthroplasty workforce can promote attention to issues that disproportionately affect historically underrepresented and vulnerable patient populations.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Silvestre J, Walker JJ, LaPorte DM, et al. Women Are Underrepresented Among Principal Investigators of Hip and Knee Arthroplasty Clinical Trials in the United States. J Bone Joint Surg Am. 2023. PMID: 37315108. doi:10.2106/JBJS.23.00205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。